about
Linear ubiquitination prevents inflammation and regulates immune signallingIAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosisNET formation can occur independently of RIPK3 and MLKL signaling.RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKLCellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitmentTumor necrosis factor (TNF) signaling, but not TWEAK (TNF-like weak inducer of apoptosis)-triggered cIAP1 (cellular inhibitor of apoptosis protein 1) degradation, requires cIAP1 RING dimerization and E2 binding.TNFR1-dependent cell death drives inflammation in Sharpin-deficient mice.In TNF-stimulated cells, RIPK1 promotes cell survival by stabilizing TRAF2 and cIAP1, which limits induction of non-canonical NF-kappaB and activation of caspase-8TRAF2 regulates TNF and NF-κB signalling to suppress apoptosis and skin inflammation independently of Sphingosine kinase 1Unravelling the complexities of the NF-kappaB signalling pathway using mouse knockout and transgenic models.TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha.Bcl-2 family proteins: the sentinels of the mitochondrial apoptosis pathway.TRAF2 must bind to cellular inhibitors of apoptosis for tumor necrosis factor (tnf) to efficiently activate nf-{kappa}b and to prevent tnf-induced apoptosis.RIPK1/RIPK3 promotes vascular permeability to allow tumor cell extravasation independent of its necroptotic function.Combination of IAP antagonist and IFNγ activates novel caspase-10- and RIPK1-dependent cell death pathways.Regulating the balance between necroptosis, apoptosis and inflammation by inhibitors of apoptosis proteins.Targeting of Fn14 Prevents Cancer-Induced Cachexia and Prolongs Survival.TNF induced inhibition of Cirbp expression depends on RelB NF-κB signalling pathway.Necroptosis Execution Is Mediated by Plasma Membrane Nanopores Independent of Calcium.Correction: TRAF2 regulates TNF and NF-κB signalling to suppress apoptosis and skin inflammation independently of Sphingosine kinase 1.In TNF-stimulated cells, RIPK1 promotes cell survival by stabilizing TRAF2 and cIAP1, which limits induction of non-canonical NF-κB and activation of caspase-8.Cell death research, on an island girt by sea.Response to Heard et al.Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics.Loss of BID Delays FASL-Induced Cell Death of Mouse Neutrophils and Aggravates DSS-Induced Weight Loss.Autoreactive T cells induce necrosis and not BCL-2-regulated or death receptor-mediated apoptosis or RIPK3-dependent necroptosis of transplanted islets in a mouse model of type 1 diabetes.Inhibitor of apoptosis proteins are required for effective fusion of autophagosomes with lysosomes.Determinants of sensitivity to lovastatin-induced apoptosis in multiple myelomaThe Ubiquitin Ligase XIAP Recruits LUBAC for NOD2 Signaling in Inflammation and Innate ImmunityTargeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-MimeticscIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1- and RIPK3-dependent mannerTumor necrosis factor (TNF) signaling, but not TWEAK (TNF-like weak inducer of apoptosis)-triggered cIAP1 (cellular inhibitor of apoptosis protein 1) degradation, requires cIAP1 RING dimerization and E2 bindingAnother facet of ubiquitylation: deathTNFR2 induced priming of the inflammasome leads to a RIPK1-dependent cell death in the absence of XIAPCorrection: TNFR2 induced priming of the inflammasome leads to a RIPK1-dependent cell death in the absence of XIAPCaspase-8 modulates physiological and pathological angiogenesis during retina developmentSMAC mimetics promote NIK-dependent inhibition of CD4+ TH17 cell differentiation
P50
Q24298581-806FC9F7-7F9D-421A-BF50-0B0DFC990290Q24300734-CD2F282C-5739-41EA-8317-58693D759783Q27335473-067EE125-868B-456A-B0CD-C8F326F951EAQ30623992-C82A231C-756B-4116-AB68-CD5574E4E995Q33589801-93E28D98-D976-478F-BC3F-5E3928A99D17Q33885155-1AE61650-585E-40A5-A80E-A54CB6FFE7FEQ34729606-F3821435-DC3A-422C-8C92-889E3AF0C419Q34787151-6B898A9E-915C-4852-ABC2-A60799B2DDA7Q36624553-A518876F-B47C-4590-96A7-2E24939BCF50Q36637897-136BA4D2-5C89-4878-884C-6FF1A4A5BDDFQ36749651-1C77366E-4CED-4F79-92A8-DBFA4B793925Q37143362-9A7AB1E4-2D5A-4940-991A-6BB83E5A1B4AQ37467736-999BE08E-560F-43A1-928E-54E043361DAAQ38984566-75A20AED-6D26-40DB-BB83-AE95E53CFE5EQ39010178-EF42EF97-3188-41D6-9947-76D645F26B26Q39025072-D0BD5FD9-001E-429E-9E0D-4D742922477AQ40550049-D082A0BD-488F-40DE-B1F0-57B3F2761210Q41683475-D0144B20-8422-4412-8008-961A275FC2F2Q42210642-F97DC102-BF82-4F29-819F-829AA3A0E9F7Q42334089-71A4C9FB-2A10-467B-9063-6014D9269BFEQ42535796-039196D1-5E73-4FE8-86E1-B6CADE2F1F8EQ43175705-72A01140-BBFF-441C-84B1-F954FAEAC8C9Q43226237-CFEF5DF2-80C8-4E4A-8ED0-4456AA3FA69FQ52885510-6DD6325A-331E-4903-9FEC-4B9BA1E65672Q54263952-CDAEFF41-E5D4-41C3-9F5A-792ED1067973Q55070749-3E11A3CA-F048-4F51-A2C0-70EDBD2AA391Q55217026-D7507B0C-F9E4-4821-8335-C72D8188BDF4Q57288643-988E9B5B-E8F2-41A2-BB08-1D3BC6E77921Q57334872-8B094E80-01E1-4A7D-A59E-7BD55F745A02Q57663672-4D3A0575-3DE1-4894-B0C2-3C53AF7B844EQ62817637-7875B8EC-0D96-444D-B35B-76B56B37F252Q62820245-B125E024-9A6D-413C-97EC-73C65BC9AECEQ84614660-024A858F-5734-4F05-ABF9-835143F0D58AQ90196931-E3E609E3-C21C-4C3F-B1B1-EF5195B03740Q92889913-45C69E82-132A-441E-BF2E-2CD897076A1FQ92900445-60D85847-68ED-4681-8BA4-ED92E35B961EQ92913051-1A10F691-B58C-4175-8AF5-EC8406B98E3D
P50
description
onderzoeker uit Zwitserland
@nl
researcher
@en
հետազոտող
@hy
name
W. Wei-Lynn Wong
@ast
W. Wei-Lynn Wong
@en
W. Wei-Lynn Wong
@es
W. Wei-Lynn Wong
@nl
W. Wei-Lynn Wong
@sq
type
label
W. Wei-Lynn Wong
@ast
W. Wei-Lynn Wong
@en
W. Wei-Lynn Wong
@es
W. Wei-Lynn Wong
@nl
W. Wei-Lynn Wong
@sq
prefLabel
W. Wei-Lynn Wong
@ast
W. Wei-Lynn Wong
@en
W. Wei-Lynn Wong
@es
W. Wei-Lynn Wong
@nl
W. Wei-Lynn Wong
@sq
P106
P27
P31
P496
0000-0003-3155-1211